Where systems biology, root-cause thinking, and standard eye care meet.

What does it actually mean to practice integrative ophthalmology, and how is it different from the eye care most patients already know? In this episode, Dr. Saikumar Gandapodi, Board-Certified Doctor of Oriental Medicine, Ayurvedic practitioner, and Founder of Netra Eye Institute, sits down to define an emerging clinical discipline that treats the eye as part of the whole body rather than an isolated organ.

We explore where conventional ophthalmology excels, where chronic eye disease leaves gaps, and how concepts like ocular blood flow, oxidative stress, inflammation, and the gut-eye axis are being studied as contributors to disease. Dr. Gandapodi explains Netra Restoration Therapy as a multi-target, adjunctive approach, and he is candid throughout about what is established versus what remains early and hypothesis-generating.

This is a research-driven conversation for an educated audience curious about the future of eye health, told without hype and without dismissing the surgery and pharmaceuticals that save sight every day.

[on-hold music] Welcome to the Netra Eye Institute Podcast,

where modern vision science meets the wisdom of integrative ophthalmology.

Today, we are joined by Dr. Saikumar Gandapodi,

founder and director of Netra Eye Institute,

whose work is dedicated to redefining how patients understand and approach chronic

and degenerative eye conditions. His goal is simple:

to help patients, families, and clinicians explore a more comprehensive and

integrative approach to long-term eye health.

This is the Netra Eye Institute Podcast. Let's begin.

[on-hold music] Welcome to the Netra Eye Institute Podcast,

where modern vision science meets the wisdom of integrative ophthalmology.

Today, we are joined by Dr. Saikumar Gandapodi,

founder and director of Netra Eye Institute,

whose work is dedicated to redefining how patients understand and approach chronic

and degenerative eye conditions.

His goal is simple:

to help patients, families, and clinicians explore a more comprehensive and

integrative approach to long-term eye health.

This is the Netra Eye Institute Podcast. Let's begin.

Welcome to the show.

Today, we're trying to pin down something that's talked about a lot but rarely

integrative ophthalmology. My guest is Dr. Saikumar Gandapodi,

board-certified doctor of Oriental medicine, an Ayurvedic practitioner, and

the founder and director of Netra Eye Institute. Dr. Gandapodi, thanks for being

-here. -Thanks for having me. It's a topic I care

about, partly because the term gets used loosely, and I think patients deserve a

clearer picture of what it does and doesn't mean.

Let's start there. If a patient asks you what integrative ophthalmology is, what do

you tell them?

I tell them it's standard eye care plus a systems view.

We keep the diagnostics, the surgery, the medications, all of it. Then we ask what

else in the body might be feeding a chronic eye problem and whether we can

support the tissue through more than one pathway.

-So it's additive, not a replacement. -Correct. If someone has a retinal

detachment or acute angle-closure glaucoma, they need an ophthalmologist and

often an operating room, not a tea. Integrative work lives mostly in the

chronic, slow, multifactorial diseases where we have gaps.

What are those gaps in your view? Where does conventional care hit its limits?

Conventional care is excellent at the mechanical and the acute.

Lower the eye pressure, remove the cataract, inject anti-VEGF for wet macular

degeneration.

Where it's honestly still limited is slowing chronic degeneration once pressure

or a single target is controlled and the disease keeps creeping.

Glaucoma is the classic example there, isn't it? Pressure controlled, but

-progression continues. -It is. Lowering intraocular pressure is

the one intervention we know changes the course, and it's essential.

But a subset of patients keep losing retinal ganglion cells at normal

pressures.

That tells us other factors are in play.

What factors?

What does the evidence actually point to?

In glaucoma specifically, there's real interest in ocular blood flow and vascular

dysregulation,

in oxidative stress at the optic nerve head,

and in the loss of neurotrophic support to retinal ganglion cells.

Some of this is well documented mechanistically.

The treatment implications are still being worked out.

Let's slow down on blood flow.

Why would that matter if pressure is fine?

The optic nerve needs steady perfusion.

In some patients, you see poor autoregulation,

cold hands and feet,

low nighttime blood pressure, migraines. Studies have linked this vascular

dysregulation to normal tension glaucoma.

It's a plausible evidence-supported contributor, though not the whole story.

And neurotrophins?

You mentioned support to ganglion cells.

Molecules like BDNF help keep retinal ganglion cells alive.

In animal models of glaucoma, BDNF signaling drops, and boosting it protects

cells.

That's compelling lab and animal work.

We don't yet have a proven deliver-to-the-eye human therapy from it,

and I want to be clear about that.

That distinction between animal models and human trials comes up a lot in this

-space. -Constantly. A lot of neuroprotection looks

beautiful in a rodent and disappoints in people.

So when I talk to patients, I separate established from promising in humans, from

still just mechanistic.

Those are three different confidence levels.

Let's talk about the other big chronic condition,

age-related macular degeneration.

-Where does the systems view fit there? -AMD is where integrative thinking has its

strongest, most established foothold. And interestingly, it came out of conventional

research.

The AREDS and AREDS2 trials showed a specific antioxidant and zinc formula

slows progression to advanced AMD in the right patients.

That's diet and micronutrients changing an eye disease proven in large trials.

So mainstream ophthalmology already prescribes a nutritional intervention.

Every day.

AREDS2 added lutein and zeaxanthin, carotenoids that concentrate in the

macula.

That’s the bridge I point to.

The idea that the eye responds to nutrition and oxidative stress control

isn’t fringe.

It’s in the standard of care for AMD.

What’s driving AMD at the tissue level that these things address?

Oxidative stress on the retinal pigment epithelium, chronic low-grade

inflammation, and there’s growing evidence involving the complement system and

drusen formation.

Antioxidants and macular pigment address part of the oxidative piece.

They don’t touch everything, which is why AREDS slows but doesn’t stop it.

You’ve mentioned the gut-eye axis in past talks. Is that real science, or is that a

stretch?

It’s real, but early.

There’s emerging research associating gut microbiome composition and systemic

inflammation with AMD and with diabetic eye disease.

Most of it is associational or in animals right now.

I’d call it a genuine research frontier,

not something to build firm treatment promises on yet.

That’s a helpful honesty.

Let’s bring in the traditional systems you’re trained in.

How do Ayurveda and Chinese medicine fit into a modern evidence framework?

I treat their concepts as interpretive frameworks, not literal biology.

When Chinese medicine describes blood stasis,

I read that as a lens that overlaps but what we’d call impaired microcirculation.

It’s a parallel, not a one-to-one scientific equivalent, and I’m careful

never to blur that line.

Give me an Ayurvedic example the same way.

Ayurveda talks about pitta and about rakta dhatu, roughly the blood tissue.

A pitta inflammatory pattern maps loosely onto what we’d study as inflammatory and

oxidative processes.

Again, that’s me translating an old framework into modern terms for

orientation,

not claiming they’re identical.

And the herbs themselves?

Skeptics hear herbal and think folk remedy.

Fair skepticism, but modern pharmacology looks at these formulas as complex

mixtures of phytochemicals hitting several targets at once.

That’s the network pharmacology idea.

A single formula might have compounds that are antioxidant, anti-inflammatory, and

support microcirculation together.

Is there a specific botanical with decent eye-relevant evidence?

Saffron is one I’ll name because it has actual human data.

Small randomized trials in AMD have suggested modest functional benefit.

They’re small and need replication,

so I present it as promising in early human studies, not proven.

Ginkgo has been studied in glaucoma blood flow, also preliminary.

You’re consistently hedging. Do patients find that frustrating?

Some do at first, but most feel respected once they realize I’m not selling

certainty.

The honest answer to, “Will this work?” is often, “It may help. Here’s the level of

evidence, and it won’t replace your injections or your drops.”

That’s a good moment to define Netra Restoration Therapy.

-What is it concretely? -NRT is our structured integrative program.

The idea is multi-target. Instead of one lever, we try to support several pathways

relevant to a given chronic eye disease at once alongside the patient’s standard

-care. -Which pathways in practice?

Depending on the diagnosis, it might touch ocular blood flow, oxidative stress

reduction, inflammatory balance, mitochondrial support, and general

cellular resilience, plus the whole body basics: sleep, blood sugar, blood

pressure.

For a glaucoma patient, we’d emphasize perfusion and neuroprotection concepts.

For AMD, the oxidative and inflammatory side.

How do you keep that from becoming a kitchen sink approach where you throw

everything at the wall?

By anchoring to the specific disease biology and by not overloading

and by measuring.

We track the standard clinical markers with the treating ophthalmologist,

visual fields, OCT, pressures, so we’re not flying on vibes.

If something isn’t moving the needle, we don’t keep doing it.

Let me ask the hard question directly. Does NRT cure anything?

No. I make no cure claims and no guarantees. It’s adjunctive and

complementary.

The goal is to support the tissue and the whole person while conventional care does

the heavy lifting.

Anyone promising to cure glaucoma or reverse advanced AMD with herbs is not

being straight with you.

What about dry eye and the ocular surface?

That feels like natural integrative territory.

It is, and the evidence is friendlier there.

Dry eye and meibomian gland dysfunction are inflammatory tear film problems.

Omega-3s have mixed but real trial data.

Lid hygiene and warm compresses are standard, and diet and systemic

inflammation clearly interact with the ocular surface. It’s a good example of

-body and eye being one system. -You mentioned mitochondria a moment ago.

Why would that be relevant to the eye?

The retina is one of the most metabolically demanding tissues in the

body.

Photoreceptors and the optic nerve burn enormous energy,

so mitochondrial health matters.

There’s genuine research interest in mitochondrial dysfunction in glaucoma and

AMD.

It’s mechanistically strong. Targeted human therapies are still emerging.

Where do you see this discipline going in the next decade?

I hope toward rigor.

More real trials of these adjuncts, better biomarkers so we can personalize, and

closer collaboration where the ophthalmologist and the integrative

practitioner share the same chart.

The future isn’t alternative versus conventional. It’s one team.

If a patient listening wants to explore this responsibly,

what should they do?

Keep your ophthalmologist central and never stop prescribed treatment on your

own.

Ask any integrative provider what the evidence level is for each recommendation,

and watch for red flags, cure promises, or pressure to abandon standard care.

Good integrative care embraces your eye doctor. It doesn’t compete with them.

Last question.

What’s the single takeaway you want people to hold onto?

That the eye is not an isolated organ and that treating the whole person is

compatible with the best of modern ophthalmology, not opposed to it. Do both

honestly and measure what you’re doing.

Dr. Gandapodi, this has been a genuinely clear-eyed conversation,

no pun intended.

Thank you.

My pleasure. Thanks for keeping it grounded.

Welcome to the show. Today, we’re trying to pin down something that’s talked about

a lot but rarely defined well: integrative ophthalmology. My guest is Dr.

Saikumar Gandapodi, board-certified doctor of Oriental medicine, an Ayurvedic

practitioner, and the founder and director of Netra Eye Institute. Dr. Gandapodi,

-thanks for being here. -Thanks for having me. It’s a topic I care

about, partly because the term gets used loosely, and I think patients deserve a

clearer picture of what it does and doesn’t mean.

Let’s start there. If a patient asks you what integrative ophthalmology is, what do

-you tell them? -I tell them it’s standard eye care plus a

systems view.

We keep the diagnostics, the surgery, the medications, all of it. Then we ask what

else in the body might be feeding a chronic eye problem and whether we can

support the tissue through more than one pathway.

-So it’s additive, not a replacement. -Correct. If someone has a retinal

detachment or acute angle-closure glaucoma, they need an ophthalmologist and

often an operating room, not a tea. Integrative work lives mostly in the

chronic, slow, multifactorial diseases where we have gaps.

What are those gaps in your view? Where does conventional care hit its limits?

Conventional care is excellent at the mechanical and the acute.

Lower the eye pressure, remove the cataract, inject anti-VEGF for wet macular

degeneration.

Where it’s honestly still limited is slowing chronic degeneration once pressure

or a single target is controlled and the disease keeps creeping.

Glaucoma is the classic example there, isn’t it? Pressure controlled, but

-progression continues. -It is.

Lowering intraocular pressure is the one intervention we know changes the course,

and it’s essential.

But a subset of patients keep losing retinal ganglion cells at normal

pressures.

-That tells us other factors are in play. -What factors? What does the evidence

actually point to?

In glaucoma specifically, there’s real interest in ocular blood flow and vascular

dysregulation,

in oxidative stress at the optic nerve head,

and in the loss of neurotrophic support to retinal ganglion cells.

Some of this is well-documented mechanistically.

The treatment implications are still being worked out.

Let’s slow down on blood flow.

Why would that matter if pressure is fine?

The optic nerve needs steady perfusion.

In some patients, you see poor autoregulation,

cold hands and feet,

low nighttime blood pressure, migraines.

Studies have linked this vascular dysregulation to normal tension glaucoma.

It’s a plausible evidence-supported contributor, though not the whole story.

And neurotrophins?

You mentioned support to ganglion cells.

Molecules like BDNF help keep retinal ganglion cells alive.

In animal models of glaucoma, BDNF signaling drops, and boosting it protects

cells.

That’s compelling lab and animal work.

We don’t yet have a proven deliver-to-the-eye human therapy from it,

and I want to be clear about that.

That distinction between animal models and human trials

-comes up a lot in this space. -Constantly.

A lot of neuroprotection looks beautiful in a rodent and disappoints in people.

So when I talk to patients, I separate established from promising in humans from

still just mechanistic.

Those are three different confidence levels.

Let’s talk about the other big chronic condition,

age-related macular degeneration. Where does the systems view fit there?

AMD is where integrative thinking has its strongest, most established foothold, and

interestingly, it came out of conventional research.

The AREDS and AREDS2 trials showed a specific antioxidant and zinc formula

slows progression to advanced AMD in the right patients.

That's diet and micronutrients changing an eye disease, proven in large trials.

So mainstream ophthalmology already prescribes a nutritional intervention.

Every day.

AREDS2 added lutein and zeaxanthin, carotenoids that concentrate in the

macula.

That's the bridge I point to.

The idea that the eye responds to nutrition and oxidative stress control

isn't fringe. It's in the standard of care for AMD.

What's driving AMD at the tissue level that these things address?

Oxidative stress on the retinal pigment epithelium, chronic low-grade

inflammation, and there's growing evidence involving the complement system and

drusen formation.

Antioxidants and macular pigment address part of the oxidative piece.

They don't touch everything, which is why AREDS slows but doesn't stop it.

You've mentioned the gut-eye axis in past talks. Is that real science, or is that a

stretch?

It's real, but early. There's emerging research associating gut microbiome

composition and systemic inflammation with AMD and with diabetic eye disease.

Most of it is associational or in animals right now.

I'd call it a genuine research frontier, not something to build firm treatment

promises on yet.

That's a helpful honesty.

Let's bring in the traditional systems you're trained in.

How do Ayurveda and Chinese medicine fit into a modern evidence framework?

I treat their concepts as interpretive frameworks, not literal biology.

When Chinese medicine describes blood stasis,

I read that as a lens that overlaps with what we'd call impaired microcirculation.

It's a parallel, not a one-to-one scientific equivalent, and I'm careful

never to blur that line.

Give me an Ayurvedic example the same way.

Ayurveda talks about pitta and about rakta dhatu, roughly the blood tissue.

A pitta inflammatory pattern maps loosely onto what we'd study as inflammatory and

oxidative processes.

Again, that's me translating an old framework into modern terms for

orientation,

not claiming they're identical.

And the herbs themselves?

Skeptics hear herbal and think folk remedy.

Fair skepticism, but modern pharmacology looks at these formulas as complex

mixtures of phytochemicals hitting several targets at once.

That's the network pharmacology idea.

A single formula might have compounds that are antioxidant, anti-inflammatory, and

-support microcirculation together. -Is there a specific botanical with decent

eye-relevant evidence?

Saffron is one I'll name because it has actual human data.

Small randomized trials in AMD have suggested modest functional benefit.

They're small and need replication,

so I present it as promising in early human studies, not proven.

Ginkgo has been studied in glaucoma blood flow, also preliminary.

You're consistently hedging.

Do patients find that frustrating?

Some do at first, but most feel respected once they realize I'm not selling

certainty.

The honest answer to, "Will this work?" is often, "It may help. Here's the level of

evidence, and it won't replace your injections or your drops."

That's a good moment to define Netra Restoration Therapy.

-What is it concretely? -NRT is our structured integrative program.

The idea is multi-target. Instead of one lever, we try to support several pathways

relevant to a given chronic eye disease at once, alongside the patient's standard

-care. -Which pathways in practice?

Depending on the diagnosis, it might touch ocular blood flow, oxidative stress

reduction, inflammatory balance, mitochondrial support, and general

cellular resilience, plus the whole body basics: sleep, blood sugar, blood

pressure.

For a glaucoma patient, we'd emphasize perfusion and neuroprotection concepts.

For AMD, the oxidative and inflammatory side.

How do you keep that from becoming a kitchen sink approach, where you throw

everything at the wall?

By anchoring to the specific disease biology and by not overloading

and by measuring.

We track the standard clinical markers with the treating ophthalmologist, visual

fields, OCT, pressures, so we're not flying on vibes.

If something isn't moving the needle, we don't keep doing it.

Let me ask the hard question directly. Does NRT cure anything?

No,

I make no cure claims and no guarantees. It's adjunctive and complementary.

The goal is to support the tissue and the whole person while conventional care does

the heavy lifting.

Anyone promising to cure glaucoma or reverse advanced AMD with herbs is not

being straight with you.

What about dry eye and the ocular surface?

That feels like natural integrative territory.

It is, and the evidence is friendlier there.

Dry eye and meibomian gland dysfunction are inflammatory tear film problems.

Omega-3s have mixed but real trial data.

Lid hygiene and warm compresses are standard, and diet and systemic

inflammation clearly interact with the ocular surface. It’s a good example of

-body and eye being one system. -You mentioned mitochondria a moment ago.

Why would that be relevant to the eye?

The retina is one of the most metabolically demanding tissues in the

body.

Photoreceptors and the optic nerve burn enormous energy, so mitochondrial health

matters.

There’s genuine research interest in mitochondrial dysfunction in glaucoma and

AMD.

It’s mechanistically strong. Targeted human therapies are still emerging.

Where do you see this discipline going in the next decade?

I hope toward rigor,

more real trials of these adjuncts, better biomarkers so we can personalize, and

closer collaboration where the ophthalmologist and the integrative

practitioner share the same chart.

The future isn’t alternative versus conventional. It’s one team.

If a patient listening wants to explore this responsibly,

what should they do?

Keep your ophthalmologist central and never stop prescribed treatment on your

own.

Ask any integrative provider what the evidence level is for each recommendation,

and watch for red flags, cure promises, or pressure to abandon standard care.

Good integrative care embraces your eye doctor. It doesn’t compete with them.

Last question. What’s the single takeaway you want people to hold onto?

That the eye is not an isolated organ and that treating the whole person is

compatible with the best of modern ophthalmology, not opposed to it.

Do both honestly and measure what you’re doing.

Dr. Gandapodi, this has been a genuinely clear-eyed conversation,

no pun intended.

Thank you.

My pleasure. Thanks for keeping it grounded